The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C09 | Agents acting on the renin-angiotensin system | |
| 3 | C09C | Angiotensin II antagonists, plain | |
| 4 | C09CA | Angiotensin II antagonists, plain | |
| 5 | C09CA03 | Valsartan |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 80 mg |
| Active Ingredient | Description | |
|---|---|---|
| Valsartan |
Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1-receptor subtype, which is responsible for the known actions of angiotensin II. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CODAVAL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| DIOVAN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| TROVAL Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| VALSARTAN Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| VAPRESS Film-coated tablet | Web Search | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
